Barely Significant
← all excerpts

Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

Biomedicines · 2024 · PMC11505228 · PMID 39457640

Europe PMCDOI
1
hedged sentence
0.0530
closest p · 1.1× alpha
0.0530
boldest claim

The sentences

borderline significantp = 0.053so close (0.05 < p ≤ 0.1)
Change in VCTE In the random effects model assessing change in VCTE, FGF21 demonstrated a significant standardized mean difference (SMD) of −1.71 (95% CI: −3.11 to −0.31, p = 0.017) compared to placebo, while Resmetirom showed a borderline significant effect with an SMD of −1.68 (95% CI: −3.38 to 0.02, p = 0.053) ( Figure 4 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.